Clinical Trial Update: Trastuzumab in Treating Patients With Recurrent Osteosarcoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating trastuzumab for recurrent osteosarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma | Phase 2 | Status: COMPLETED